Institute of Cancer Research launch “Darwinian” cancer drug programme

The Institute of Cancer Research has launched the world’s first ‘Darwinian’ cancer drug programme, aiming to deliver step change in cancer treatment. The programme is specially designed to tackle cancer’s lethal ability to evolve resistance to treatment and is to be launched in a £75 million state-of-the-art global centre of expertise in anti-evolution therapies in

Continue Reading

New cancer blood test breakthrough

Scientists from Johns Hopkins University have taken a step towards one of the biggest goals in medicine, a universal blood test for cancer. The researchers have trialled a method that can detect up to eight common forms of the disease. The scientists envision the research to be developed into an annual test designed to catch

Continue Reading

CRUK and Institute of Cancer Research, London collaborate with Merck in new drug discovery alliance

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs. “It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and

Continue Reading

Research shows fat cells may render chemotherapeutic drugs inactive

Previous research has shown that obesity is associated with poorer outcomes from several kinds of cancer, including breast, colon, ovarian, and prostate cancers. New research suggests that excess adiposity can affect the “pharmacokinetics” of chemotherapy, or the way drugs are absorbed, metabolised, and excreted from the body. Steven Mittelman, MD, PhD, Associate Professor of Paediatrics

Continue Reading

Ground breaking Artificial Intelligence System has ability to identify 97% of those at risk of breast cancer

Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that has the ability to diagnose patients with breast cancer 97% of the time. The current screening process for breast cancer involves a mammogram and in the event of abnormal cells are identified, a needle biopsy is the next

Continue Reading

Giant genome study of lung cancer susceptibility leads to new causes being identified

A huge study has identified several new variants for lung cancer risk that will lead to better understanding of the mechanisms involved in lung cancer risk. Using the OncoArray genotyping platform developed by multiple cancer consortia, a large aggregated genomewide association study, identified new susceptibility loci for lung cancer, the leading cause of cancer mortality

Continue Reading

Novartis set to join forces with IBM Watson Health to tackle breast cancer.

The multinational pharmaceutical company and IBM Watson are teaming up in a “ground-breaking collaboration” that aims to combine machine learning with real-world data to improve outcomes in advanced breast cancer. Both parties are planning to explore development of a ‘cognitive solution’ that will provide improved insights on the potential outcomes of breast cancer treatment options,

Continue Reading